Bronchodilating Beta-agonist compositions and methods
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/167
A61P-011/08
출원번호
US-0336972
(2011-12-23)
등록번호
US-8623922
(2014-01-07)
발명자
/ 주소
Banerjee, Partha S.
Chaudry, Imtiaz A.
Pham, Stephen
출원인 / 주소
Dey Pharma, L.P.
대리인 / 주소
McDermott Will & Emery LLP
인용정보
피인용 횟수 :
1인용 특허 :
115
초록▼
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoc
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
대표청구항▼
1. A pharmaceutical composition, comprising formoterol, or a pharmaceutically acceptable derivative thereof selected from the group consisting of salts, esters, enol ethers, enol esters, acids, bases, solvates, hydrates and prodrugs, in a pharmacologically suitable fluid, wherein the composition is
1. A pharmaceutical composition, comprising formoterol, or a pharmaceutically acceptable derivative thereof selected from the group consisting of salts, esters, enol ethers, enol esters, acids, bases, solvates, hydrates and prodrugs, in a pharmacologically suitable fluid, wherein the composition is stable during long term storage and the fluid comprises water, and wherein the formoterol free base concentration is about 0.08 μg/mL up to about 128 μg/mL. 2. The pharmaceutical composition of claim 1, wherein the composition has an estimated shelf-life of greater than 1 month usage time at 25° C. and greater than or equal to 1 year storage time at 5° C. 3. The pharmaceutical composition of claim 1, wherein greater than about 80% of the initial formoterol is present after 1 month usage time at 25° C. and 1 year storage time at 5° C. 4. The pharmaceutical composition of claim 1 that has been nebulized. 5. The pharmaceutical composition of claim 1, wherein the pharmacologically suitable fluid comprises a polar solvent. 6. The pharmaceutical composition of claim 5, wherein the polar solvent is a protic solvent. 7. The pharmaceutical composition of claim 1, further comprising a tonicity adjusting agent. 8. The pharmaceutical composition of claim 7, wherein the tonicity adjusting agent is ammonium carbonate, ammonium chloride, ammonium lactate, ammonium nitrate, ammonium phosphate, ammonium sulfate, ascorbic acid, bismuth sodium tartrate,, calcium chloride, calcium disodium edetate, calcium gluconate, calcium lactate, citric acid, dextrose, diethanolamine, dimethylsulfoxide, edetate disodium, edetate trisodium monohydrate, fluorescein sodium, fructose, galactose, glycerin, lactic acid, lactose, magnesium chloride, magnesium sulfate, mannitol, polyethylene glycol, potassium acetate, potassium chlorate, potassium chloride, potassium iodide, potassium nitrate, potassium phosphate, potassium sulfate, propylene glycol, silver nitrate, sodium acetate, sodium bicarbonate, sodium biphosphate, sodium bisulfite,, sodium bromide, sodium cacodylate, sodium carbonate, sodium chloride, sodium citrate, sodium iodide, sodium lactate, sodium metabisulfite, sodium nitrate; sodium nitrite, sodium phosphate, sodium propionate, sodium succinate, sodium sulfate, sodium sulfite, sodium tartrate, sodium thiosulfate, sorbitol, sucrose, tartaric acid,, urea, urethan, uridine or zinc sulfate. 9. The pharmaceutical composition of claim 7, wherein the tonicity adjusting agent is sodium chloride. 10. The pharmaceutical composition of claim 1, wherein the pharmacologically suitable fluid comprises a buffer. 11. The pharmaceutical composition of claim 10, wherein the buffer is citric acid/phosphate, acetate, barbital, Britton-Robinson, cacodylate, citrate, collidine, formate, maleate, McIlvaine, phosphate, Prideaux-Ward, succinate,), verona acetate, MES (2-(N-morpholino)ethanesulfonic acid), ADA (N-(2-acetamido)-2-iminodiacetic acid), ACES (N-(carbamoylmethyl)-2-aminoethanesulfonic acid), PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)), MOPSO (3-(N-morpholino)-2-hydroxypropanesulfonic acid), BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), TES (N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid), HEPES (N-(2-hydroxyethyl)piperazine-N-(2-ethanesulfonic 20 acid), DIPSO (3-(N,N-bis(2-hydroxyethyl)amino)-2-hydroxypropanesulfonic acid), MOBS (4-(N-morpholino)butanesulfonic acid), TAPSO (3-(N-tris(hydroxymethyl)-methylamino)-2-hydroxypropanesulfonic acid), HEPPSO(N-(2-hydroxyethyl)piperazine-N′-(2-hydroxypropanesulfonic acid), POPSO (piperazine-N,N′-bis(2-hydroxypropanesulfonic acid)), EPPS(N-(2-hydroxyethyppiperazine-N′-(3-propanesulfonic acid), TRICINE (N-tris(hydroxymethyl)methylglycine), GLY-GLY (glycylglycine), BICINE (N,N-bis(2-hydroxyethyl)glycine), HEPBS (N-(2-hydroxyethyl)piperazine-N′-(4-butanesulfonic acid)), TAPS(N˜tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid), or AMPD (2-amino-2-methyl-1,3-propanediol) buffer. 12. The pharmaceutical composition of claim 10; wherein the buffer comprises citric acid/phosphate buffer, acetate buffer, citrate buffer or phosphate buffer. 13. The pharmaceutical composition of claim 10, wherein the buffer is citrate buffer. 14. The pharmaceutical composition of claim 13, wherein the buffer concentration is from about 0.01 mM to about 150 mM. 15. The pharmaceutical composition of claim 13, wherein the buffer concentration is from about 1 mM to about 50 mM. 16. The pharmaceutical composition of claim 13, wherein the buffer concentration is from about 1 mM to about 20 mM. 17. The pharmaceutical composition of claim 13, wherein the buffer concentration is about 20 mM. 18. The pharmaceutical composition of claim 13, wherein the buffer concentration is about 5 mM. 19. The pharmaceutical composition of claim 8, wherein the ionic strength of the composition is about 0 to about 0.4. 20. The pharmaceutical composition of claim 8, wherein the ionic strength of the composition is about 0.05 to about 0.16.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (115)
Jerussi Thomas P. ; Senanayake Chris Hugh, (S,R) formoterol methods and compositions.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosol formulations containing P134A and/or P227 and particulate medicament.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing propellant 134a and fluticasone propionate.
Phillipps Gordon H. (Wembley GB2) Bain Brian M. (Chalfont St. Peter GB2) Steeples Ian P. (Ruislip Manor GB2) Williamson Christopher (Cobham GB2), Androstane carbothioates.
Stefely James S. ; Schultz David W. ; Schallinger Luke E. ; Perman Craig A. ; Leach Chester L. ; Duan Daniel C., Biocompatible compounds for pharmaceutical drug delivery systems.
Dieter Hochrainer DE; Bernd Zierenberg DE, Closure-cap and container as a two-chamber cartridge for nebulizers for producing aerosols and active substance formulations, suitable for storage.
Carling Christer Carl Gustav (Dalby SEX) Trofast Jan William (Lund SEX), Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders.
Carling Christer Carl Gustav,SEX ; Trofast Jan William,SEX, Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as w.
Spear Kerry (Oakland CA) Johnson Charles (Berkeley CA) Gschwend Heinz W. (Bodega Bay CA), Compositions and methods for the treatment of immunomediated inflammatory disorders.
Caldwell Charles G. ; Chen Ping ; Durette Philippe L. ; Finke Paul ; Hale Jeffrey ; Holson Edward ; Kopka Ihor ; MacCoss Malcolm ; Meurer Laura ; Mills Sander G. ; Robichaud Albert, Cycloalkyl tachykinin receptor antagonists.
Kadlec Ronald James (Colorado Springs CO), Digital servo control system for use in disk drives, having state space observer including integral compensator.
Weers Jeffry G. ; Dellamary Luis A. ; Tarara Thomas E. ; Trevino Leo A. ; Ranney Helen M., Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents.
Trevino Leo A. ; Riess Jean G.,FRX ; Dellamary Luis A. ; Krafft Marie-Pierre,FRX ; Tarara Thomas E., Hydrocarbon oil/fluorochemical preparations and methods of use.
James S. Stefely ; David W. Schultz ; Luke E. Schallinger ; Craig A. Perman ; Chester L. Leach ; Daniel C. Duan, Medicinal aerosol solution formulation with biocompatible polymer.
Dorn Conrad P. (Plainfield NJ) Hale Jeffrey J. (Westfield NJ) Maccoss Malcolm (Freehold NJ) Mills Sander G. (Woodbridge NJ), Morpholine compounds are prodrugs useful as tachykinin receptor antagonists.
Barrett Ronald W. (Saratoga CA) England Bruce P. (Fremont CA) Schatz Peter J. (Mountain View CA) Sloan Derek (Los Gatos CA) Chen Min-Jia (San Francisco CA), Peptides and compounds that bind to the IL-5 receptor.
Barrett Ronald W. (Saratoga CA) England Bruce P. (Fremont CA) Schatz Peter J. (Mountain View CA) Sloan Derek (Los Gatos CA) Chen Min-Jia (San Francisco CA), Peptides and compounds that bind to the IL-5 receptor.
Barrett Ronald W. (Saratoga CA) England Bruce P. (Fremont CA) Schatz Peter J. (Mountain View CA) Sloan Derek (Los Gatos CA) Chen Min-Jia (San Francisco CA), Peptides and compounds that bind to the IL-5 receptor.
Barrett Ronald W. (Sunnyvale CA) England Bruce P. (Fremont CA) Schatz Peter J. (Mountain View CA) Sloan Derek (Los Gatos CA) Chen Min-Jia (San Francisco CA), Peptides and compounds that bind to the IL-5 receptor.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant.
Blondino Frank E. ; Brucato Michael ; Buenafe Maria W. ; Cavanaugh Kelly A., Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol.
Skidmore Ian F. (Welwyn GB2) Lunts Lawrence H. C. (Broxbourne GB2) Finch Harry (Hitchin GB2) Naylor Alan (Royston GB2), Phenethanolamine derivatives having b2-adrenoreceptor selective stimulant action.
Bosch H. William (Bryn Mawr PA) Marcera Donna M. (Collegeville PA) Mueller Ronald L. (Downingtown PA) Swanson Jon R. (Macungie PA) Mishra Dinesh S. (Harleysville PA), Process for preparing therapeutic compositions containing nanoparticles.
Eva Bernini IT; Chiara Malvolti IT; Raffaella Garzia IT; Gaetano Brambilla IT; Paolo Chiesi IT, Process for the preparation of suspensions of drug particles for inhalation delivery.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Liversidge Gary G. (West Chester PA) Conzentino ; Jr. Philip (West Chester PA) Cundy Kenneth C. (Pottstown PA) Sarpotdar Pramod P. (Malvern PA), Surface modified NSAID nanoparticles.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.